GR3033268T3 - Highly efficient production and isolation of viral particles - Google Patents

Highly efficient production and isolation of viral particles

Info

Publication number
GR3033268T3
GR3033268T3 GR20000400951T GR20000400951T GR3033268T3 GR 3033268 T3 GR3033268 T3 GR 3033268T3 GR 20000400951 T GR20000400951 T GR 20000400951T GR 20000400951 T GR20000400951 T GR 20000400951T GR 3033268 T3 GR3033268 T3 GR 3033268T3
Authority
GR
Greece
Prior art keywords
exchange resin
viral particles
isolation
cells
highly efficient
Prior art date
Application number
GR20000400951T
Other languages
English (en)
Inventor
Christopher P Prior
David M Weber
Richard S Gore
Michael E Hrinda
Jonathan J Mitschelen
Thomas W Irish
Pierre M Bay
George C Tarr
James J Harter
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Publication of GR3033268T3 publication Critical patent/GR3033268T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR20000400951T 1994-03-22 2000-04-19 Highly efficient production and isolation of viral particles GR3033268T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21583394A 1994-03-22 1994-03-22
PCT/US1995/003668 WO1995025789A1 (en) 1994-03-22 1995-03-22 Highly efficient production and isolation of viral particles

Publications (1)

Publication Number Publication Date
GR3033268T3 true GR3033268T3 (en) 2000-09-29

Family

ID=22804586

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000400951T GR3033268T3 (en) 1994-03-22 2000-04-19 Highly efficient production and isolation of viral particles

Country Status (12)

Country Link
US (2) US5661023A (el)
EP (1) EP0751988B1 (el)
JP (1) JP3313117B2 (el)
AT (1) ATE189697T1 (el)
AU (1) AU2127395A (el)
CA (1) CA2186034C (el)
DE (1) DE69515028T2 (el)
DK (1) DK0751988T3 (el)
ES (1) ES2141929T3 (el)
GR (1) GR3033268T3 (el)
PT (1) PT751988E (el)
WO (1) WO1995025789A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69515028T2 (de) * 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
EP0944717A1 (fr) 1996-07-01 1999-09-29 Aventis Pharma S.A. Procede de production d'adenovirus recombinants
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
JP2001514845A (ja) * 1997-09-05 2001-09-18 ターゲティッド ジェネティクス コーポレイション 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法
JP2002500088A (ja) * 1998-01-12 2002-01-08 ハー マジェスティ イン ライト オブ カナダ アズ リプレゼンティッド バイ ザ ミニスター オブ アグリカルチャー アンド アグリ−フード カナダ 非極性抽出物の単離、回収及び精製方法
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples
EP1284287A4 (en) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp METHOD FOR PRODUCING A VIRUS VECTOR
US20020177571A1 (en) 2000-11-29 2002-11-28 Gordon Erlinda M. Targeted vectors for cancer immunotherapy
DE50213362D1 (de) * 2001-02-11 2009-04-30 Aquanova Ag Verfahren zur herstellung eines isoflavon-konzentrats
US20030031626A1 (en) * 2001-07-26 2003-02-13 Thomas Rheinlander Process for the production of pharmaceutical preparations
DE10137515A1 (de) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Verfahren zur Herstellung pharmazeutischer Zubereitungen
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP1815029A4 (en) 2004-11-03 2009-06-10 Introgen Therapeutics Inc NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
PL2307551T3 (pl) 2008-06-18 2017-07-31 Oxford Biomedica (Uk) Limited Oczyszczanie wektorów retrowirusowych
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CN103476399A (zh) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
WO2014043644A1 (en) 2012-09-17 2014-03-20 Alltech Associates, Inc. Functionalized particulate support material and methods of making and using the same
RU2015114330A (ru) 2012-09-17 2016-11-10 У.Р. Грейс Энд Ко.-Конн. Хроматографические среды и устройства
US11229896B2 (en) 2014-01-16 2022-01-25 W.R. Grace & Co.—Conn. Affinity chromatography media and chromatography devices
JP6914189B2 (ja) 2014-05-02 2021-08-04 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 官能化担体材料並びに官能化担体材料を作製及び使用する方法
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
US12031117B2 (en) 2017-11-22 2024-07-09 Corning Incorporated Perfusion bioreactor system and perfusion cell culture method
US11028124B2 (en) 2018-05-07 2021-06-08 Repligen Corporation Methods, devices and systems for 3-stage filtration
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509070A (en) * 1968-06-13 1970-04-28 American Home Prod Adsorbent for chromatographic purification of virus
US3655509A (en) * 1969-05-29 1972-04-11 Monsanto Co Process for the separation of virus from non-viral proteins
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6151571A (ja) * 1984-08-21 1986-03-14 Nippon Seibutsu Kagaku Kenkyusho オ−エスキ−病診断用抗原の単離・精製法
ATE132374T1 (de) * 1987-06-10 1996-01-15 Immune Response Corp Inc Verhütung und behandlung einer retrovirenkrankheit
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
DE69132795T3 (de) * 1990-03-09 2008-07-10 Novartis Vaccines and Diagnostics, Inc., Emeryville Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
DE69515028T2 (de) * 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
JPH08195877A (ja) * 1995-01-18 1996-07-30 Canon Inc イメージセンサと画像処理回路

Also Published As

Publication number Publication date
DE69515028T2 (de) 2000-06-29
ES2141929T3 (es) 2000-04-01
DK0751988T3 (da) 2000-06-26
EP0751988A1 (en) 1997-01-08
EP0751988A4 (en) 1997-11-12
WO1995025789A1 (en) 1995-09-28
JPH10500286A (ja) 1998-01-13
AU2127395A (en) 1995-10-09
US6080571A (en) 2000-06-27
CA2186034C (en) 2002-11-26
CA2186034A1 (en) 1995-09-28
US5661023A (en) 1997-08-26
ATE189697T1 (de) 2000-02-15
PT751988E (pt) 2000-05-31
EP0751988B1 (en) 2000-02-09
JP3313117B2 (ja) 2002-08-12
DE69515028D1 (de) 2000-03-16

Similar Documents

Publication Publication Date Title
GR3033268T3 (en) Highly efficient production and isolation of viral particles
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
EP1325960A3 (en) Negative strand RNA virus vector having autonomously replicating activity
LU91314I9 (el)
FI962990A0 (fi) Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
AU3896595A (en) Process of imprinting catalytically active particles on membrane
WO1996013597A3 (en) Improved adenovirus and methods of use thereof
ES8702395A1 (es) Procedimiento para preparar podifilotoxina purificada
NO179074C (no) Fremgangsmåte for fremstilling av rensede glykolipider ved membranadskillelsesfremgangsmåten
YU78402A (sh) Hemostatički aktivni preparat koji sadrži vwf i postupak njegovog pripremanja
AU4440196A (en) The removal of viruses from protein solutions by ultrafiltration
AU747417C (en) Filtration method for separating viruses
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
FR2528070B1 (fr) Vecteur d'expression porteur d'un codage genetique pour une proteine liant les phosphates, procede pour sa preparation et procede de production d'un polypeptide en l'utilisant
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
AU3905893A (en) Plant resistant to two or more viruses and preparation thereof
AU574092B2 (en) Process for producing 1,3-bis(3-aminophenoxy) benzene
DE69103798D1 (de) Katalysatorsystem und -verfahren zur selektiven Herstellung von Isoprenyl-Alkylethern aus Isopren.
AU6521186A (en) Lytic viruses as expression vectors, host cell containing same and process for protein production
TW357136B (en) Process and apparatus for preparing purified water or superpurified water
EP0780398A3 (en) Process for purifying tammhorsfall glycoprotein or uromodulin, their purified products and method for making the discrimination between both of them
CA2236113A1 (en) Negative strand rna viral vector having autonomous replication capability

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees